EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND RESURFACE 2

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Mehta, N. [2 ]
Menter, A. [3 ,4 ]
Mendelsohn, A. M. [5 ]
Rozzo, S. [5 ]
Lebwohl, M. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Baylor Scott & White, Div Dermatol, Dallas, TX USA
[4] Texas A&M Coll Med, Div Dermatol, Dallas, TX USA
[5] Sun Pharmaceut Ind Inc, Med Affairs, Princeton, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1827
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0544
引用
收藏
页码：1304 / 1305
页数：2
相关论文
共 50 条
  • [21] The maintenance of effect with tildrakizumab over 5 years is independent of baseline characteristics: pooled analysis of the phase 3 studies reSURFACE 1 and reSURFACE 2 in patients with moderate to severe psoriasis
    Thaci, Diamant
    Piaserico, Stefano
    Diemert, Sebastian
    Torres, Tiago
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 60
  • [22] Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years
    Thaci, Diamant
    Piaserico, Stefano
    Du Jardin, Kristian Gaarn
    Warren, Richard B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (04) : E501 - E504
  • [23] The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: Post hoc analysis of 2 phase 3 trials (reSURFACE 1 and reSURFACE 2)
    Mehta, Nehal N.
    Lebwohl, Mark G.
    Leonardi, Craig
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Myers, Jill
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB131 - AB131
  • [24] Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
    Reich, K.
    Warren, R. B.
    Iversen, L.
    Puig, L.
    Pau-Charles, I.
    Igarashi, A.
    Ohtsuki, M.
    Falques, M.
    Harmut, M.
    Rozzo, S.
    Lebwohl, M. G.
    Cantrell, W.
    Blauvelt, A.
    Thaci, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (03) : 605 - 617
  • [25] The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
    Menter, M. Alan
    Mehta, Nehal N.
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Leonardi, Craig
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 703 - 708
  • [26] Tildrakizumab provides early predictability of response in patients with moderate to severe psoriasis: Results from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Warren, Richard B.
    Iversen, Lars
    Puig, Luis
    Fumero, Emilio
    Ryzhkova, Anna
    Schoenenberger Lopez, Andreu
    Feldman, Steven R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB10 - AB10
  • [27] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, D.
    Jullien, D.
    Egeberg, A.
    Carrascosa, J. M.
    Wu, J. J.
    Pau-Charles, I.
    Gisondi, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
  • [28] Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment
    Jackson, J. Mark
    Alexis, Andrew
    Kucera, Kristine
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Gorelick, Joseph
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB79 - AB79
  • [29] During the Treatment with Tildrakizumab 100 mg in Patients who achieved PASI <3 at Week 28, the high Treatment Response is maintained for 5 Years: Pooled Analysis of the Studies reSURFACE 1 and reSURFACE 2
    Augustin, M.
    Diemert, S.
    Pau-Charles, I
    Thaci, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 59 - 60
  • [30] Safety of tildrakizumab 100 mg and 200 mg through 5 years of exposure in reSURFACE 2
    Albrecht, Lorne
    Han, George
    Cantrell, Wendy
    Nguyen, Andrea
    Mendelsohn, Alan
    Rozzo, Stephen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB80 - AB80
12345